The most widely used medications for neuropathy fall into three main classes: anticonvulsants like gabapentin and pregabalin, antidepressants like duloxetine and amitriptyline, and topical treatments like lidocaine patches and high-concentration capsaicin. Only a handful of these carry specific FDA approval for neuropathic pain, but doctors regularly prescribe others based on strong clinical evidence. The right choice depends on the type of neuropathy you have, your other health conditions, and how you respond to side effects.
Anticonvulsants: Gabapentin and Pregabalin
Gabapentin and pregabalin are among the most commonly prescribed medications for nerve pain. They were originally developed for epilepsy, but they work on neuropathy by binding to a specific part of calcium channels on nerve cells. This reduces the release of excitatory chemical signals at nerve junctions, which quiets the overactive pain signaling that characterizes neuropathy.
Pregabalin is FDA-approved for diabetic peripheral neuropathy, with a starting dose of 150 mg per day that can be increased to a maximum of 300 mg daily based on how well it works and how you tolerate it. Common side effects include dizziness, dry mouth, blurred vision, weight gain, and drowsiness. At the highest prescribed doses (600 mg/day, used in some clinical trials), side effects become much more frequent: dizziness in about 70% of patients, blurred vision in 63%, and headache in 31%.
Gabapentin works through a similar mechanism but isn’t FDA-approved specifically for diabetic neuropathy. It’s widely used off-label and appears in most clinical guidelines as a first-line option. Both medications are cleared through the kidneys, so if you have any degree of kidney impairment, your doctor will need to lower the dose accordingly. Both also cause sedation and dizziness, which makes falls a real concern for older adults.
Antidepressants That Treat Nerve Pain
Two types of antidepressants are used for neuropathy, and they work at doses lower than what’s needed to treat depression. The pain-relieving effect also kicks in faster than the antidepressant effect and doesn’t depend on improving your mood.
Duloxetine, an SNRI, is FDA-approved for diabetic peripheral neuropathy at a usual dose of 60 mg per day. It’s also the only medication currently recommended by the American Society of Clinical Oncology for chemotherapy-induced peripheral neuropathy, based on a phase III trial showing significant pain improvement after just five weeks. Common side effects include nausea, dry mouth, drowsiness, decreased appetite, and constipation.
Tricyclic antidepressants (TCAs) like amitriptyline and nortriptyline are older medications that remain effective for many types of nerve pain. In head-to-head comparisons, TCAs show similar pain relief to gabapentin and pregabalin. Interestingly, fewer patients drop out of TCA treatment due to side effects compared to SNRIs and opioids. That said, TCAs carry their own risks: they can cause heart rhythm changes, sedation, dry mouth, and constipation. They’re contraindicated after a heart attack or in people with certain heart rhythm abnormalities, and they pose a higher fall risk for elderly patients.
Why the Type of Neuropathy Matters
Not every neuropathy medication works for every type of nerve damage. This distinction matters most for chemotherapy-induced peripheral neuropathy (CIPN). Gabapentin, pregabalin, and tricyclic antidepressants, all standard treatments for other forms of neuropathy, have failed to show benefit in clinical trials for CIPN. A phase III trial found no improvement from gabapentin in patients who had received common chemotherapy drugs, and a separate trial showed pregabalin was no better than placebo at preventing or treating chemotherapy-related nerve symptoms. Duloxetine is the clear first choice here.
For diabetic peripheral neuropathy specifically, five treatments have FDA approval: duloxetine, pregabalin, tapentadol extended-release (an opioid-like pain reliever), a high-dose capsaicin patch, and spinal cord stimulation devices. Your doctor will typically start with duloxetine or pregabalin before considering the others.
Topical Treatments
Topical options are appealing because they act locally and cause fewer body-wide side effects. Two are formally licensed for neuropathic pain: the lidocaine 5% medicated plaster and the capsaicin 8% patch.
The lidocaine plaster is specifically approved for post-herpetic neuralgia, the nerve pain that lingers after shingles. It numbs the skin in the painful area and can be applied directly over the affected site. When compared head-to-head with pregabalin, it provided similar pain relief for post-herpetic neuralgia, though it didn’t meet the strict statistical threshold for being formally declared equivalent.
The capsaicin 8% patch (brand name Qutenza) works differently. Capsaicin is the compound that makes chili peppers hot, and at this concentration it temporarily overwhelms and then desensitizes the nerve fibers in the skin that transmit pain signals. It was approved in 2020 for neuropathic pain associated with diabetic peripheral neuropathy of the feet. Each application involves placing the patch for 30 minutes, and treatments can be repeated every three months or longer. The main side effect is a transient burning sensation at the application site. In head-to-head testing, the capsaicin 8% patch demonstrated comparable effectiveness to pregabalin across a range of peripheral neuropathy types.
Opioids and Opioid-Like Medications
Opioids are generally reserved as second- or third-line treatments for neuropathic pain because of their poor long-term tolerability and the risk of dependence. Tramadol, a milder opioid, appears in some guidelines as an option when first-line treatments don’t provide enough relief.
Tapentadol extended-release is the one opioid-class drug with FDA approval for diabetic neuropathy pain, but its approval is limited to cases “severe enough to require daily, around-the-clock, long-term opioid treatment” where other options haven’t worked. It combines opioid activity with a secondary mechanism that blocks the reuptake of a brain chemical involved in pain suppression, which may reduce some typical opioid side effects like cognitive impairment. Even so, common side effects include nausea, constipation, vomiting, dizziness, and drowsiness.
For chemotherapy-induced neuropathy, opioids are not recommended. They risk unnecessary side effects and potential addiction without addressing the underlying nerve problem.
Third-Line and Less Common Options
When first-line medications fail or can’t be tolerated, several other options exist. Older anticonvulsants like carbamazepine, lamotrigine, and oxcarbazepine are sometimes tried, though they have less evidence behind them and lamotrigine requires a very slow dose increase over one to two months to reduce the risk of a serious skin rash.
Venlafaxine, another SNRI, appears in guidelines at various levels depending on the specific type of neuropathy. SSRIs like citalopram and paroxetine have some evidence but are considered third-line at best. Doctors may also combine medications from different classes, for example pairing an anticonvulsant with an antidepressant, when a single drug doesn’t provide adequate relief.
How Long Before They Work
One of the most common frustrations with neuropathy medications is the wait. Once you reach an effective dose, pain relief typically takes up to a week to develop. But reaching that dose can take longer, because most of these drugs need to be started low and gradually increased to minimize side effects. With some medications like lamotrigine, titration alone can take one to two months.
There’s no strong evidence base for how long you should stay on a neuropathy medication once it’s working. Current practice is to continue the effective dose for several months, then try reducing it to see if the pain has improved on its own. No clinical trials have run longer than six weeks, so long-term treatment decisions are based on clinical experience rather than hard data.
Special Considerations for Older Adults
Many neuropathy patients are older, and age changes the risk calculation for nearly every option. Gabapentin, pregabalin, tricyclic antidepressants, and opioids all cause sedation, dizziness, and increased fall risk in elderly or frail patients. Tricyclic antidepressants carry additional concerns about heart rhythm and are flagged on the Beers Criteria, a list of medications that are potentially inappropriate for older adults. Gabapentin and pregabalin require dose reductions in anyone with declining kidney function, which is common with age. Both anticonvulsants and antidepressants carry FDA black box warnings regarding use in patients with depression and suicidal thoughts, regardless of age.